Seattle Genetics is a biotechnology company that mainly develops and commercializes antibody-drug conjugates. The ADCs are antibodies designed to control the targeting capability of monoclonal antibodies by connecting them with cell-killing agents. The ADCs are meant to spare non-targeted cells hence reducing the harmful effects of traditional chemotherapy. The ADCs also have the ability to enhance antitumor activity. The company has its headquarters in Bothell, Washington (a suburb of Seattle) and is the industry leader in developing antibody-drug conjugates.
The company has a flagship product known as Adcetris which is the first approved product in their new class of ADCs. According to the company’s CEO, Clay Siegall, the drug is currently being tested in more than 70 clinical trials for the treatment of various types of lymphomas. The Adcetris is currently commercially available in more than 65 countries including the United States, Japan, Canada and some member countries of the European Union.
In the United States and Canada alone, the drug reported sales of $226 million in 2015. In 2016, the sale of the drug in the two countries was estimated to be in the range of $255 million to $275. The company is developing 12 other ADC drugs as well as two drugs for bladder cancer and one for breast cancer.
In the meantime, the company is hiring a big way to aid in the research of its new drugs. It plans to hire 100 employees in the United States and almost 20 in its offices in Switzerland. The firm has already hired 800 employees in its other branches around the world.
About Clay Siegall
Clay Siegall is the co-founder, chief executive officer, president and the chairman of the board of Seattle Genetics. Dr. Siegall founded Seattle Genetics on a strong foundation of scientific innovation, continuous research and a passion for helping cancer patients and those with chronic illnesses.
The scientist has guided the company to its current position as a leader in the production of antibody conjugates (ADCs). He has also raised substantial amounts of finances for his company to assist in research and developing cancer treatments. As a leading producer of the first approved ADC product, Seattle Genetics has been able to report a profit of $100 million in the second quarter of this year.